Breast Cancer

Incidence

§ 210,000 new cases annually

§ 40,000 deaths

§ Decreased by 2.3% from 1990 - 2002

5 yr Survival

§ 90% white

§ 76% African American

§ Reflects access to screening mammography, CBE

Risk Factors

§ Age >50

§ Family History

§ LCIS or atypical hyperplasia

§ Dense breast tissue

§ BRCA mutation

Types

Invasive

Ductal

Lobular

Mucinous

Tubular

Non-invasive

DCIS (does not metastasize)

Diagnosis

§ Mammogram is a SCREENING TOOL

§ FNA

§ Excisional Bx

§ Core Bx

§ Sterotactic BX

Who to MRI?

§ Known BRCA mutation

§ First degree relative with BRCA mutation

§ 20% risk based on validated model (BRACA-Pro)

§ Other familial syndrome

§ Cowden, Li-Fraummeni, HNPCC

§ Hx of chest wall RT btwn 10-30yr of age

§ e.g. Hodgkins disease

Staging

Treatment

§ Surgical Treatment

§ Mastectomy

§ Breast conversation

§ Lumpectomy with XRT

§ Equal outcomes!

Hormonal Treatment

§ ER, PR, Her 2 nu status

§ Adjunct therapy to minimize risk of recurrence

§ Tamoxifen

§ Aromatase inhibitor (Irimidex)

§ Herceptin

Survival -/+ adjuvant tx

§ T1a: 95% 96%

§ T1b: 90% 93%

§ T1c: 80% 86.5%

§ T2aN0: 70% 80%

§ T2bN1: 60% 73%

§ T3aN0: 70% 80%

§ T3bN1: 40% 60%

§ TXNXM1: >

Tamoxifen

§ 5 yrs duration (newer data to support 10)

§ Decreases recurrence risk by 37-54%

§ Increases overall survival by 11-34%

§ Monitor for development of endometrial cancer